Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

R-CHOP regimen

View Patient Information
A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CHOP-rituximab
cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine
R-CHOP
Rituxan/CHOP
rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone regimen
rituximab/cyclophosphamide/doxorubicin/prednisone/vincristine
Abbreviation:CTX/DOX/MOAB IDEC-C2B8/PRED/VCR
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search